Allergology International (Jul 2020)
Japanese guidelines for childhood asthma 2020
- Hirokazu Arakawa,
- Yuichi Adachi,
- Motohiro Ebisawa,
- Takao Fujisawa,
- Hirokazu Arakawa,
- Yuichi Adachi,
- Motohiro Ebisaw,
- Takao Fujisawa,
- Akira Akasawa,
- Toshishige Inoue,
- Yukihiro Ohya,
- Makoto Kameda,
- Kazuyuki Kurihara,
- Naoki Shimojo,
- Yutaka Suehiro,
- Hiroyuki Mochizuki,
- Shigemi Yoshihara,
- Takashi Iwanaga,
- Haruo Kuroki,
- Masato Takase,
- Ikuyo Masuko,
- Kota Hirai,
- Koichi Yoshida,
- Yuzaburo Inoue,
- Mizuho Nagao,
- Yumiko Miyaji,
- Misa Iio,
- Yasunori Ito,
- Takumi Takizawa,
- Masaki Futamura,
- Junichiro Tezuka,
- Hironobu Fukuda,
- Yukinori Yoshida,
- Hajime Nishimoto,
- Tatsuki Fukuie,
- Sakura Sato,
- Yoshiyuki Yamada,
- Ikuo Okafuji,
- Kiwako Yamamoto-Hanada,
- Mari Sasaki,
- Yuya Tanaka,
- Yoichi Nakajima,
- Atsushi Isozaki,
- Eisuke Inage,
- Hisako Yagi,
- Mayu Shimizu,
- Kenichi Akashi,
- Norio Kawamoto,
- Tetsuharu Manabe,
- Hiroki Murai,
- Yuri Takaoka,
- Taro Miura,
- Yukiko Hiraguchi,
- Takeshi Sugiyama,
- Mayumi Sugimoto,
- Shuichi Suzuki,
- Osamu Natsume,
- Hiroshi Kitazawa,
- Akiko Yamaide,
- Takuya Wada,
- Sankei Nishima
Affiliations
- Hirokazu Arakawa
- Department of Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan; Corresponding author. Department of Pediatrics, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan.
- Yuichi Adachi
- Department of Pediatrics, University of Toyama, Toyama, Japan
- Motohiro Ebisawa
- Department of Allergy, Clinical Research Center for Allergology and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan
- Takao Fujisawa
- National Hospital Organization, Mie National Hospital, Mie, Japan
- Hirokazu Arakawa
- Yuichi Adachi
- Motohiro Ebisaw
- Takao Fujisawa
- Akira Akasawa
- Toshishige Inoue
- Yukihiro Ohya
- Makoto Kameda
- Kazuyuki Kurihara
- Naoki Shimojo
- Yutaka Suehiro
- Hiroyuki Mochizuki
- Shigemi Yoshihara
- Takashi Iwanaga
- Haruo Kuroki
- Masato Takase
- Ikuyo Masuko
- Kota Hirai
- Koichi Yoshida
- Yuzaburo Inoue
- Mizuho Nagao
- Yumiko Miyaji
- Misa Iio
- Yasunori Ito
- Takumi Takizawa
- Masaki Futamura
- Junichiro Tezuka
- Hironobu Fukuda
- Yukinori Yoshida
- Hajime Nishimoto
- Tatsuki Fukuie
- Sakura Sato
- Yoshiyuki Yamada
- Ikuo Okafuji
- Kiwako Yamamoto-Hanada
- Mari Sasaki
- Yuya Tanaka
- Yoichi Nakajima
- Atsushi Isozaki
- Eisuke Inage
- Hisako Yagi
- Mayu Shimizu
- Kenichi Akashi
- Norio Kawamoto
- Tetsuharu Manabe
- Hiroki Murai
- Yuri Takaoka
- Taro Miura
- Yukiko Hiraguchi
- Takeshi Sugiyama
- Mayumi Sugimoto
- Shuichi Suzuki
- Osamu Natsume
- Hiroshi Kitazawa
- Akiko Yamaide
- Takuya Wada
- Sankei Nishima
- Journal volume & issue
-
Vol. 69,
no. 3
pp. 314 – 330
Abstract
The Japanese Guideline for Childhood Asthma (JGCA) 2020 is a translation of the Japanese Pediatric Guideline for the Treatment and Management of Asthma (JPGL) 2017 into English, which was published by the Japanese Society of Pediatric Allergy and Clinical Immunology. It makes recommendations for best practices in the management of childhood asthma, including management of acute exacerbations and non-pharmacological and pharmacological management. These guidelines will be of interest to non-specialist physicians involved in the care of children with asthma. In JPGL, JPGL2017 is the first evidence-based guidelines updated according to the GRADE system and Minds approach, and it addresses eight clinical questions about the treatment of childhood asthma. In children aged ≤5 years, infant and preschool asthma is diagnosed according to the response to short acting beta2 agonists or the effect of a therapeutic trial during 1 month with controller treatment and worsening after treatment cessation. Long-term management both promotes pharmacological therapy and measures against risk factors that induce exacerbation, better patient education and a partnership with trinity. In addition, long-term management should not be carried out without review but rather be based on a cycle of evaluation, adjustment and treatment. In JPGL2017, the transdermal patch and oral beta2 agonists are positioned as drugs within the concept of “short-term additional treatment” to be used until the symptoms are stabilized when the control state transiently deteriorates.
